FDA Hits Zhejiang Huahai for Contamination Investigation

Drug GMP Report
The FDA issued a warning letter to Chinese API maker Zhejiang Huahai, the company implicated in a global recall of contaminated valsartan, for failing to adequately investigate the root cause of the NDMA contamination at its Linhai, Taizhou Zhejiang facility.

To View This Article:


Subscribe To Drug GMP Report

Buy This Article Now

Add this article to your cart for $40.00